The French social security should stop reimbursing patients for homeopathic drugs due to insufficient effectiveness, France’s health watchdog recommended, Reuters reports.
For nine months the HAS watchdog investigated the effects of the alternative medicine on 24 medical conditions. These included anxiety, foot warts and acute breathing infections.
The watchdog announced it did not find sufficient scientific evidence to justify continued state reimbursement of homeopathic drugs.
Health minister Agnes Buzyn will now make a decision based on the recommendation.
Shares of French pharmaceutical lab Boiron, one of the world’s leading homeopathic drug makers, were suspended from trading in May and again earlier this week after details of the HAS recommendation were disclosed by French media, Reuters reports.
The end of reimbursement in France would be a blow for the firm, which depends on the French market for about 60% of its 605 million euros annual revenues.